Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering

Rhea-AI Summary

Scopus BioPharma Inc. (Nasdaq: SCPS) announced the closing of a $9 million follow-on public offering, successfully issuing 1,000,000 shares at $9.00 per share. The company also granted underwriters a 45-day option to purchase up to 150,000 additional shares. Proceeds from this offering will primarily be used to further develop its lead drug candidate, a targeted immuno-oncology gene therapy aimed at treating multiple cancers. The offering statement was filed with the U.S. Securities and Exchange Commission and became qualified on January 26, 2021.

Positive

• Raised $9 million to advance drug development.
• Funds will support development of lead immuno-oncology gene therapy.

Negative

• Potential dilution for existing shareholders due to share offering.

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the closing of a $9 million follow-on public offering.  The offering consisted of 1,000,000 shares of common stock at a public offering price of $9.00 per share.  The company has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the public offering price.

Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries.  The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.  This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.

Scopus intends to use the proceeds of the offering principally for further development of the company's lead drug candidate, including in combination with checkpoint inhibitors.

The Benchmark Company, LLC acted as Sole Bookrunning Manager and Joseph Gunnar & Co., LLC acted as Co-Manager for the offering.

Greenberg Traurig, LLP is acting as counsel to the company.  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is acting as counsel to the underwriters.

An offering statement relating to the shares of common stock was filed with the U.S. Securities and Exchange Commission and became qualified on January 26, 2021. The offering is being made only by means of an offering circular, copies of which may be obtained, when available, by contacting: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at prospectus@benchmarkcompany.com; or Joseph Gunnar & Co., LLC, Attention: Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, by calling (212) 440-9600 or by email at prospectus@jgunnar.com.  The offering circular is also available on the U.S. Securities and Exchange Commission website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Scopus BioPharma

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions.  The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.  The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.

Forward-Looking Statements

This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's offering circular filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

Contact

Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com

 

View original content:http://www.prnewswire.com/news-releases/scopus-biopharma-announces-closing-of-9-million-follow-on-public-offering-301218401.html

SOURCE Scopus BioPharma Inc.

FAQ

What is Scopus BioPharma's recent public offering?

Scopus BioPharma recently closed a $9 million public offering involving 1,000,000 shares priced at $9.00 each.

What is the intended use of proceeds from the SCPS offering?

The proceeds will primarily be used for the further development of Scopus BioPharma's lead drug candidate.

When was the offering statement for SCPS filed?

The offering statement was filed and became qualified on January 26, 2021.

How many additional shares can underwriters purchase in the SCPS offering?

Underwriters have a 45-day option to purchase up to 150,000 additional shares.